In this project, my team and I focused on seeing if a combination drug therapy using Alpelisib (ALP) and Temozolomide (TMZ) would have a synergistic effect in treating brain cancer, specifically glioblastoma. The study had two main parts. The first was to determine cell viability accessed via a CCK-8 assay to determine the effects of ALP, TMZ, and a combination of the two drugs on the specific U87-EGFP cell line. The second part of the study was to determine the drug mechanism by focusing on PI3K Activity which was looked at using a Muse PI3K Activation Dual Detection Kit. The final report of the study can be found on the right.